Although several cases showed a possible benefit of GPIIb/IIIaI in patients with COVID-19, right now there is no study examining the specificity of GPIIb/IIIaI use in COVID-19 versus non-COVID-19 cardiac patients. Here, ITGA2B is linked to COVID-19.